GAVISCON LEMON FLAVOUR

Riik: Iirimaa

keel: inglise

Allikas: HPRA (Health Products Regulatory Authority)

Toimeaine:

ALGINIC ACID SODIUM BICARBONATE ALUMINIUM HYDROXIDE GEL MAGNESIUM TRISILICATE

Saadav alates:

Reckitt Benckiser Ireland Ltd

Annus:

500/170/10 Milligram

Ravimvorm:

Tablets Chewable

Loa andmise kuupäev:

1998-10-02

Toote omadused

PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Gaviscon Tablets - Lemon Flavour 
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 500mg Alginic Acid, 170mg Sodium Bicarbonate,
100mg Aluminium Hydroxide Gel and 
25mg Magnesium Trisilicate.
For excipients, see 6.1
3 PHARMACEUTICAL FORM
Chewable tablet.
Circular, flat, off-white to cream, bevel-edged tablets with
a sword logo on each face and an odour of lemon.
4 CLINICAL PARTICULARS 
4.1 THERAPEUTIC INDICATIONS
Gastric reflux, reflux oesophagitis, heartburn, hiatus hernia,
flatulence associated with gastric reflux and heartburn of 
pregnancy. All cases of epigastric and
retrosternal distress where the underlying
cause is gastric reflux. Treatment of 
regurgitation.
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
For oral administration, after being thoroughly chewed.
Adults and children over 12
years: One or two tablets after meals and at bedtime.
Elderly: No dose modification is required in this age group.
Children 6 to 12 years: One tablet after meals and at bedtime.
Children 2 to 6 years: Should be given only on
medical advice. Dose - one tablet after meals and at bedtime.
Infants: Not recommended.
4.3 CONTRAINDICATIONS
None known.
4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
Sodium content of a tablet is 47 mg (2.04 mmol). This should
be taken into account when a highly restricted salt diet is 
required as in some renal and cardiovascular conditions.
Aluminium hydroxide may cause constipation due to
its astringent action; this effect may be balanced by
the cathartic 
effect of the magnesium salts.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Issued 22/09/2005_
_CRN 2014941_
_page number: 1_
Aluminium hydroxide may lead to a phosphate depletion syndrome,
particularly